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A universal immunisation programme against varicella 
in the form of the measles-mumps-rubella-varicella 
(MMRV) vaccine for toddlers aged 13–15 months was 
introduced in Tuscany in July 2008. An assessment 
of the impact of this programme on varicella-related 
hospitalisations 4 years after its introduction could 
further support its adoption at a national level. The 
hospitalisation data were analysed in two periods: 
pre-vaccination (2004–2007) and vaccination period 
(2009–2012). The high coverage of the vaccines (84% 
in 2012) resulted in a significant decline in notifi-
cations, from 33,114 (2004–2007) to 13,184 cases 
(2009–2012), and also of hospitalisations, from 584 
(pre-vaccination period) to 325 (vaccination period). 
The hospitalisation rate was 4.1 per 100,000 (95% 
confidence intervals (CI): 3.4–4.7) before the introduc-
tion of vaccination, which dropped to 2.2 per 100,000 
(95% CI: 1.7–2.7) in the vaccination period (hospitali-
sation risk ratios: 0.54; 95% CI:  0.472–0.619). The 
reduction was most significant in the youngest age 
groups. The introduction of universal vaccination has 
already led to a significant decline in hospitalisations 
due to varicella after just 4 years of implementation. 
Hospitalisation rates fell noticeably among younger 
individuals involved in the vaccination programme. 
The decrease in hospitalisation rate in the older age 
groups suggests a possible indirect protection.
Introduction
Varicella (chickenpox) is the primary manifestation of 
infection with the varicella zoster virus (VZV) and is a 
widespread and highly contagious infectious disease. 
Today, varicella is recognised as the most common 
exanthematic disease in children in Italy, with an esti-
mated number of 500,000 new cases each year [1,2]. 
Seroprevalence studies confirm that VZV infection is 
still predominantly a paediatric infection in Italy, and 
that there are no substantial differences between 
blood samples collected in 1996–1997 and those col-
lected in 2003–2004 [2,3].
An effective and safe monovalent varicella vaccine 
has been available in Italy since 1995. However, vari-
cella immunisation has not been widely adminis-
tered in Italy in the previous decades. In the National 
Vaccination Plan 2005–2007, the varicella vaccine 
was recommended only to individuals with a high risk 
of complications and to susceptible adolescents [4]. 
However, in order to avoid a shift in the median age 
of VZV infection towards adulthood, the plan advised 
introduction of routine childhood varicella vaccina-
tion in regions that have been able to achieve and 
maintain high vaccination coverage against measles, 
mumps and rubella (MMR) [4]. As a result of these indi-
cations, universal immunisation against varicella was 
not homogeneously implemented at the national level 
[5,6]. According to an earlier survey of vaccination cov-
erage carried out in Italy by the National Institute of 
Health (Istituto Superiore di Sanità), the reported child-
hood vaccination coverage, involving one dose of the 
varicella vaccine at 24 months of age, was only 17.1% 
(range: 15.7–18.6%) in Italy in 2008 [7].
In the Italian National Vaccination Plan 2012–2014, 
(which is the schedule currently being used in 2016) 
the implementation of universal varicella vaccina-
tion at the national level was pushed back until such 
time when the monitoring and data evaluation of the 
pilot programmes carried out in some Italian regions 
(Basilicata, Calabria, the autonomous province of 
Bolzano, Puglia, Sardinia, Sicily, Tuscany, and Veneto) 
would be available [8]. Assessment of the epidemio-
logical and economic impact of immunisation against 
varicella through these regional programmes will ena-
ble the rationale for the aforementioned decision to be 
validated. At the time of publication, the evaluation 
and related implementation at the national level have 
not yet been performed.
Tuscany was one of the first Italian regions to introduce 
and implement a universal vaccination programme 
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against varicella with a combined MMRV vaccine for 
children aged 13–15 months (first dose) and 5 to 6 
years (second dose), in July 2008 [9]. The impact of this 
preventive intervention was evaluated 4 years after the 
implementation.
In particular, the objective of our study is to evaluate 
the impact of universal varicella vaccination in Tuscany 
by analysing all varicella-related hospitalisations 
reported in the period 2004–2012.
Methods
The hospital discharge records related to varicella were 
analysed in order to evaluate the impact of universal 
varicella vaccination on the hospitalisation rate in 
Tuscany. Hospitalisation data for 2004–2012 were col-
lected from the Tuscan regional database. In particular, 
all hospitalised cases for varicella or its complications, 
as a primary or secondary discharge diagnosis, with 
the following ICD-9-CM codes (2002 and 2007) were 
examined: 052.0 (post-varicella encephalitis), 052.1 
(varicella (haemorrhagic) pneumonitis), 052.2 (post-
varicella myelitis), 052.7 (varicella with other specified 
complications), 052.8 (varicella with unspecified com-
plication), and 052.9 (varicella without complication) 
[10].
For each hospitalised case, the collected information 
included year of hospitalisation, age at time of dis-
charge, sex, region of origin, local health unit, coun-
try of residence, hospital days, primary and up to five 
secondary diagnoses, and total cost of hospitalisation. 
The costs of hospitalisation correspond to the refund-
ing by the region to the hospitals. Costs are calculated 
according to the diagnosis-related group (DRG), and 
also include the possible costs due to the additional 
days of hospitalisation in excess of the specific out-
lier threshold. Moreover, the resident population was 
grouped by age, as retrieved by the Italian National 
Institute of Statistics database, in order to calculate 
hospitalisation rates [11].
Hospitalisation data were compared with surveillance 
data obtained from the Tuscan regional database for 
varicella cases notified in Tuscany in the same period.
In addition, data on varicella vaccine coverage in chil-
dren aged 24 months in the period 2008–2012 were 
included in the analysis. Data on vaccination coverage 
were also collected from the Tuscan regional database.
Varicella-related hospitalisations were analysed as fol-
lows: (i) in the entire period 2004–2012, in order to 
evaluate the trend over time; (ii) in two periods of 4 
years each (the pre-vaccination period, 2004–2007; 
and the period following the vaccine’s introduction, 
2009–2012). Data from 2008, the transition year 
between the two periods mentioned above, were 
excluded from our analysis. The impact of universal 
varicella vaccination was assessed by calculating the 
hospitalisation risk ratios (HRRs) with a 95% confi-
dence interval (CI) (Mantel-Haenszel combined test).
Results
Varicella vaccination in Tuscany
Inclusion of the quadrivalent combined MMRV vaccine 
in the immunisation programme led to rapid achieve-
ment of high vaccine coverage against varicella in 
Tuscany, with a relevant dragging effect. In fact, vari-
cella vaccination with MMRV or monovalent varicella 
vaccines for children at 24 months of age achieved 
high coverage soon after implementation: 75.5% in 
2010, 82.2% in 2011, and 84.0% in 2012.
Varicella cases and hospitalisations
In Tuscany, 52,738 varicella cases were notified to 
the Regional Health Authority in 2004–2012. A dra-
matic overall reduction in the number of notifications 
was reported between 2004 (11,445 cases) and 2012 
(1,502 cases). The number of reported varicella cases 
in the vaccination period (13,184 cases) has been 
reduced by more than half (60.2% reduction) of that 
in the pre-vaccination period (33,114 cases). The aver-
age incidence rate has declined from 2.30 cases (95% 
CI: 2.25–2.35) to 0.89 cases (95% CI: 0.86–0.92) per 
1,000 inhabitants.
For the same period in 2004–2012, a total of 1,022 
hospital discharge records related to varicella or its 
complications were found in Tuscany. The number of 
hospitalisations due to varicella diseases showed a 
decreasing trend over the 9 years analysed: 189 hospi-
talisations for varicella (5.3 hospitalised cases/100,000 
inhabitants; 95% CI: 4.5–6.1) were reported in 2004 
and 44 in 2012 (1.2/100,000 inhabitants; 95% CI: 0.8–
1.6). In other words, there was a substantial reduction 
in the number of hospitalisations (by 77%) between 
2004 and 2012. The incidence of notified varicella 
cases and the rate of hospitalised cases for varicella 
diseases showed the same trend in the period 2004–
2012 in Tuscany (Figure 1).
Figure 1
Hospitalisation rate for varicella diseases and incidence of 
varicella, Tuscany, Italy, 2004–2012
0
1
2
3
4
5
6
0
1
2
3
4
5
6
2004 2005 2006 2007 2008 2009 2010 2011 2012
Hospitalisation rate (per 100,000)
Incidence (per 1,000)
Year
Ho
sp
ita
lis
at
io
ns
In
ci
de
nc
e
3www.eurosurveillance.org
In the pre-vaccination period (2004–2007), there were 
584 hospitalised cases related to varicella or its com-
plications in Tuscany, while in the vaccination period 
(2009–2012) there were 325. A total reduction of 44% 
(259 fewer cases) in the number of hospitalisations due 
to varicella was observed between 2009 and 2012. In 
particular, the average hospitalisation rate for varicella 
diseases was 4.1 per 100,000 (95% CI: 3.4–4.7) in the 
period before the introduction of varicella vaccination 
in Tuscany. This dropped to 2.2 per 100,000 (95% CI: 
1.7–2.7) in the vaccination period (HRR: 0.54; 95% 
CI: 0.47–0.62).
Hospitalisations for varicella diseases analysed 
by age at time of discharge
In the period 2004–2012, the hospitalisation rates 
related to varicella or its complications showed a 
downward trend in almost all age groups, especially for 
children under 14 years of age. Children aged between 
1 and 4 years, who had historically been affected by 
varicella diseases and were enrolled in the current uni-
versal programme of varicella vaccination in Tuscany, 
appeared to be the age group that received the great-
est benefit from vaccination (a net reduction in hos-
pitalised cases by 90% in the 9-year period, from 60 
cases in 2004 to six cases in 2012, corresponding to 
a hospitalisation rate of 52.1 (95% CI: 38.9–65.3) and 
4.6 (95% CI: 0.9–8.4) per 100,000 inhabitants respec-
tively) (Figure 2).
On comparing the pre-vaccination and vaccination 
period data, the most relevant reduction (> 20%) in the 
rate of hospitalisation due to varicella diseases was 
again reported in children below 5 years of age (Table).
Hospital discharge records for varicella diseases 
analysed by discharge code
The hospital discharge records for primary and second-
ary diagnoses of varicella or its complications in the 
study period (2004–2012) were analysed. Among the 
1,022 hospitalised cases in Tuscany, a total of 1,041 
varicella-related codes (ICD-9-CM) were reported. Of 
these, 19 hospitalised cases had more than one code 
identifying varicella diseases in the discharge diagno-
sis. The most frequently reported discharge code was 
varicella without complication (052.9). In the period 
2004–2012, there were no hospitalisations for post-
varicella myelitis (ICD-9-CM 2007 code 052.2).
In the switch from the pre-vaccination years (2004–
2007) to the vaccination period (2009–2012), a net 
reduction in hospitalised cases was evident for all dis-
charge codes related to varicella. The greatest reduc-
tion in the number of hospitalised cases (178 cases) 
between the two periods (2004–2007 vs 2009–2012) 
pertained to the discharge diagnosis of varicella with-
out complications (052.9) (Figure 3). In fact, hospi-
talisations for this diagnosis decreased by 10.5% in 
individuals aged 1–14 years who were involved in the 
vaccination programme.
Total days of hospitalisation for varicella 
diseases
In the period 2004–2012, a total of 1,022 patients hos-
pitalised for varicella or its complications in Tuscany 
remained in the hospital for 6,112 days (an average 
of six hospital days per patient). The total number of 
hospital days showed a clear downward trend in the 
9 years analysed. In particular, while in 2004 patients 
were admitted for 960 days in total, in 2012 the total 
number of hospital days had decreased to 378 days, 
with an overall reduction of 61% between the first and 
the last year analysed in the study. In the pre-vaccina-
tion period (2004–2007), the total number of days hos-
pitalised was 3,388; this number decreased to 2,021 in 
the vaccination period (2009–2012), showing a reduc-
tion of 40% (1,367 days fewer). The average number of 
hospital days per patient ranged from 5.8 to 6.6 in the 
pre-vaccination and vaccination periods.
Figure 2
Hospitalisation rates for varicella, by age group, Tuscany, Italy, 2004–2012
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Cost of hospitalisations due to varicella 
diseases
In the period 2004–2012, the cost of the 1,022 hospi-
talisations for varicella or its complications in Tuscany 
amounted to EUR 2,506,422 (EUR 2,452 per patient on 
average). The total annual cost of hospitalisation has 
shown a decreasing trend in the 9 years analysed, 
similar to the trend in hospitalised cases. In particu-
lar, while 189 hospitalisations for varicella occurred 
in 2004, incurring a cost of EUR 455,267, in the final 
year of the study 44 patients were hospitalised for a 
total cost of EUR 106,311, an overall cost reduction of 
77%. In the pre-vaccination period (2004–2007) the 
total cost of hospitalisation due to varicella was EUR 
1,420,657 (EUR 355,164/year). In the vaccination period 
(2009–2012), the cost decreased to EUR 807,535 (EUR 
201,884/year). Therefore, hospital costs declined by 
43%, creating total savings of EUR 613,121, or EUR 
153,280/year.
In the switch from the pre-vaccination period (2004–
2007) to the vaccination period (2009–2012), a reduc-
tion in the total cost of hospitalisations for varicella 
diseases was reported in all age groups in Tuscany 
(Figure 4). However, the cost of hospitalisation 
increased among individuals over 64 years of age, 
though the number of hospitalised patients in this age 
group had not changed much from the pre-vaccination 
period (21 cases) to the vaccination period (25 cases). 
This slight increase in costs is mainly attributable to 
the specific case of an 80-year old patient whose pri-
mary diagnosis was pulmonary insufficiency, with sec-
ondary diagnoses including generalised convulsive 
epilepsy, cerebrovascular disease, a kidney disorder, 
and post-varicella encephalitis. This patient’s hospital 
costs amounted to EUR 34,724. The greatest reduc-
tion of hospitalisation costs in absolute number (EUR 
241,267) concerns the age group of 25–49 years (data 
not shown).
In the period 2004–2012, although the number of hos-
pitalised cases and the total annual cost of hospitalisa-
tion declined to a great extent, the cost per hospitalised 
case seemed to show a slight increasing trend over 
the 9 years analysed (Figure 5). In the pre-vaccination 
period (2004–2007), the average cost of hospitalised 
cases was EUR 2,433 per patient, while in the period of 
varicella vaccination (2009–2012), this cost increased 
by 2% to EUR 2,485, with an increment of EUR 52 in the 
average hospitalisation cost of each patient.
Discussion and conclusions
The routine immunisation of toddlers against vari-
cella has not yet been widely implemented in Europe. 
Assessment of the epidemiology and disease burden 
of varicella in each country and evidence for the effec-
tiveness of varicella vaccination could provide support 
for decision on implementation of routine childhood 
programmes [12]. Generally, only a small percentage 
of people infected with varicella diseases are hospital-
ised in Italy. However, the period 2000–2003 saw an 
Figure 3
Number of hospitalised cases for varicella diseases, by 
diagnosis codea, Tuscany, Italy, in the pre-vaccination 
(2004–2007) and vaccination periods (2009–2012)
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Total cost of hospitalisation for varicella diseases, by age 
group, Tuscany, Italy, pre-vaccination (2004–2007) and 
vaccination periods (2009–2012)
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Cost per hospitalised case for varicella diseases, Tuscany, 
Italy, 2004–2012
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annual average of 1,575 hospitalisations where vari-
cella was the primary diagnosis (1,521 hospitalisations 
and 54 day-hospital admissions) with a mean hospital 
stay of 5.3 days per person [2]. Approximately one-third 
of these cases occurred in people older than 14 years 
and could have been prevented through a programme 
of universal vaccination, including an active offer of 
varicella vaccine to adolescents and adults at high risk 
without any anamnestic history of varicella diseases 
[2].
The results of our study show that the introduction of 
a universal varicella vaccination with MMRV vaccine in 
Tuscany for all newborns has already resulted in a sig-
nificant reduction in varicella notifications as well as 
in the number of hospitalisations due to varicella and 
related costs, within the first 4 years of implementa-
tion. In particular, the current analysis highlights that 
the number of hospitalised cases has been greatly 
reduced, especially among younger individuals who 
were involved in the vaccination programme. However, 
a positive impact of vaccination on the hospitalisation 
rate is also evident in other age groups, suggesting a 
herd immunity effect. Our data on significant reduction 
of hospitalisation due to varicella in adults are com-
patible with the results published in Canada [13] and 
the United States (US) [14] but contradict the hospi-
talisation data in Germany, where results do not dem-
onstrate herd protection against varicella with 87% 
vaccination coverage [15]. In addition, the absence of 
a shift of infection time to the older age groups could 
be explained by the high vaccination coverage among 
children. Comparing hospitalisation for uncomplicated 
varicella (the most frequent discharge diagnosis) in the 
pre-vaccination period (2004–2007) and in the vac-
cination period (2009–2012), a clear reduction is evi-
dent, thus suggesting that the slight increase in the 
cost per hospitalised patient might be due to a higher 
chance that only the most severe cases were hospital-
ised during the vaccination period.
Limitations of the study are mainly due to the fact that 
our data on hospitalisations are based on administra-
tive data. A greater appropriateness of hospital admis-
sions during the examined period cannot be excluded 
as an additional factor in the reduction of hospitalisa-
tion rate. Another possible limitation is that varicella 
may have been coded as zoster or vice versa, even 
though we included only hospitalisation related to vari-
cella in the analysis. Therefore, the magnitude of the 
decline implies a marked positive effect of the rapid 
increase in the vaccination coverage, achieved due to 
the availability of the quadrivalent MMRV vaccine.
Our study confirms the remarkably favourable clinical 
impact on notified cases and varicella-related hospi-
talisations reported in two other Italian regions (Sicily 
and Veneto), a few years after the implementation 
of the immunisation programme. Sicily was the first 
Italian region to offer a universal active vaccination 
against varicella free of charge to infants at 15 months 
of age and to all susceptible adolescents at 12 years of 
age, in January 2003 [16,17].
The Veneto region adopted active and free univer-
sal varicella vaccination in January 2005 for children 
aged 14 months (offering a second dose at the age of 
6 years), and a catch-up programme for adolescents 
aged 12 years. The rapid achievement of high (but 
not optimal) coverage of vaccination against varicella 
(78.6% in the 2008 birth cohort) resulted in a net dec-
rement (halving) of the varicella incidence, both in the 
0–14 year age group and in the general population, 
within 4 years of the introduction of the varicella vac-
cination programme. Furthermore, in this region, hos-
pitalisation due to varicella infection also significantly 
decreased within 1.5 years of the introduction of the 
universal varicella vaccination, confirming a significant 
positive impact of universal varicella vaccination in 
this Italian region [18-20].
In addition, the reduction in varicella cases and number 
of related hospitalisations highlighted in Sicily, Veneto, 
Tuscany, and recently in other Italian regions [21,22], 
Table
Hospitalisations for varicella diseases, by age, and hospitalisation risk ratios with 95% CI, Tuscany, Italy, pre-vaccination 
(2004–2007) and vaccination periods (2009–2012)
  Age group  
Pre-vaccination period 2004–2007 Vaccination period 2009–2012
HRR 95% CI
Hospitalisations Average rate per 100,000 Hospitalisations
Average rate per 
100,000
< 1 year 73 59.6 42 32.7 0.55 0.38–0.80
1–4 years 189 39.5 99 18.9 0.48 0.38–0.61
5–14 years 105 9.2 55 4.5 0.48 0.35–0.67
15–24 years 32 2.6 21 1.7 0.64 0.37–1.19
25–49 years 141 2.7 67 1.3 0.47 0.35–0.63
50–64 years 23 0.8 16 0.5 0.67 0.35–1.26
> 64 years 21 0.6 25 0.7 1.14 0.64–2.04
Overall 584 4.1 325 2.2 0.54 0.47–0.62
CI: confidence interval; HRR: hospitalisation risk ratio.
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after the introduction of the universal varicella immuni-
sation programme, had already been observed in other 
countries. In the US, universal varicella vaccination 
with one-dose (1996) and two-dose (2006) schedules 
for children was demonstrated to have a clear and sig-
nificant impact on the disease burden of VZV infection 
within a few years of implementation [23-28]. In our 
recent data, obtained a few years after the start of the 
varicella immunisation programme, the number of hos-
pitalisations due to varicella shows a trend similar to 
the results reported in the US [29-35].
A relevant reduction of VZV infections and disease 
complications has also been observed in Germany, 
which was the first European country to implement a 
routine universal vaccination programme against vari-
cella in 2004 [36-38].
From an economic point of view, the universal vaccina-
tion of children in Tuscany led to savings amounting 
to EUR 613,121 over 4 years (EUR 153,280/year), con-
sidering only the potential costs of hospitalisations 
that were prevented by immunisation. In particular, a 
reduction in hospitalisation costs is evident in all age 
groups except for individuals over 64 years, where 
the high cost during the vaccination period can be 
mainly attributed to the previously described case of 
a patient aged 80 years who had other medical con-
ditions and incurred hospitalisation costs amounting 
to EUR 34,724. However, the reported savings could 
be even more substantial if it is assumed that the real 
expense is 30–40% higher than the figure calculated 
through the DRG value, as shown by Azzari et al. [39]. 
In addition, in our study, we analysed only the cost of 
hospitalisations due to VZV infection: savings follow-
ing vaccination would have greatly increased if we also 
included the other clinical costs and indirect costs 
due to productivity loss. Therefore, the data we col-
lected in a real-setting scenario seem to confirm the 
favourable economic contribution of varicella immuni-
sation in Italy, as previously reported in three Italian 
model-based evaluations [40-42]. Particularly in the 
mathematic simulation performed by Bonanni et al., 
a varicella vaccination programme with two doses for 
toddlers was predicted to lead to reduction by more 
than 80% in VZV infection and hospitalisation rate in 
a 30-year time horizon [42]. The results of our study 
show a 44% reduction in the rate of hospitalisation due 
to varicella within 4 years of the introduction of vari-
cella vaccination, confirming the model’s mathematical 
forecast.
In conclusion, our experience clearly supports the 
intention of the Italian health authorities to introduce 
a national universal routine vaccination against vari-
cella. The use of the quadrivalent MMRV vaccine is a 
key element to achieving high vaccination coverage in 
a short period of time, thus speeding up the impact 
on disease incidence and related hospitalisations. The 
Italian regional vaccination programmes against vari-
cella may also prove to be a useful example for other 
countries where the introduction of routine toddler vac-
cination is being considered.
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